Reuter M A, Loenicker E M, Reuter H J
Fortschr Med. 1981 May 7;99(17):654-8.
In 100 patients with urinary tract infections the new benzyl-pyrimidine/sulphonamide combination Co-tetroxazin (Sterinor) was tested concerning its in vitro and in vivo action. In spite of the heterogenous cases (pyelonephritis 16%, obstructions 15%, prostatitis respectively urethritis 12% and cystitis 53%) and the relatively high average age (about 40% above the age of 60) a high therapeutic success was achieved. The clinical symptomatology improved up to 96% (respectively 83% without anymore pathological findings). This in vivo action correlated very well with the in vitro action in the agar diffusion test: fully sensitive 79%, moderately sensitive 15% and resistant only 6%. It is worth mentioning that the in vivo results with Sterinor were obtained with only 1/3 of the usual substance load (dosis) of the other benzylpyrimidine/sulphonamide combinations. This is due to the more favourable pharmacokinetic properties. Particularly in chronic patients, multi-morbidity and in elder patients this is clinically relevant. With this proven comparable clinical effect Co-tetroxazin is to be specified therefore to be more effective pharmacologically.
对100例尿路感染患者测试了新型苄基嘧啶/磺胺组合药物Co - tetroxazin（Sterinor）的体外和体内作用。尽管病例各异（肾盂肾炎占16%，梗阻占15%，前列腺炎或尿道炎占12%，膀胱炎占53%）且平均年龄相对较高（60岁以上约占40%），但仍取得了较高的治疗成功率。临床症状改善率高达96%（无任何病理结果者为83%）。这种体内作用与琼脂扩散试验中的体外作用相关性非常好：完全敏感占79%，中度敏感占15%，耐药仅占6%。值得一提的是，Sterinor的体内试验结果是在仅为其他苄基嘧啶/磺胺组合常用药物剂量的1/3的情况下获得的。这归因于更有利的药代动力学特性。特别是在慢性病患者、多病共存患者和老年患者中，这具有临床相关性。鉴于已证实的可比临床效果，因此可以确定Co - tetroxazin在药理上更有效。
